NASDAQ:IMUX Immunic (IMUX) Stock Price, News & Analysis $1.00 +0.04 (+4.53%) Closing price 02/14/2025 04:00 PM EasternExtended Trading$1.01 +0.01 (+1.50%) As of 02/14/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Immunic Stock (NASDAQ:IMUX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immunic alerts:Sign Up Key Stats Today's Range$0.97▼$1.0550-Day Range$0.94▼$1.3252-Week Range$0.92▼$2.11Volume907,061 shsAverage Volume992,769 shsMarket Capitalization$90.08 millionP/E RatioN/ADividend YieldN/APrice Target$12.67Consensus RatingBuy Company OverviewImmunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.Read More… Immunic Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks42nd Percentile Overall ScoreIMUX MarketRank™: Immunic scored higher than 42% of companies evaluated by MarketBeat, and ranked 699th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingImmunic has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageImmunic has only been the subject of 2 research reports in the past 90 days.Read more about Immunic's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Immunic are expected to grow in the coming year, from ($0.94) to ($0.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunic is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunic is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunic has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Immunic's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.16% of the outstanding shares of Immunic have been sold short.Short Interest Ratio / Days to CoverImmunic has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Immunic has recently increased by 6.53%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunic does not currently pay a dividend.Dividend GrowthImmunic does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.16% of the outstanding shares of Immunic have been sold short.Short Interest Ratio / Days to CoverImmunic has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Immunic has recently increased by 6.53%, indicating that investor sentiment is decreasing significantly. News and Social Media1.3 / 5News Sentiment-0.58 News SentimentImmunic has a news sentiment score of -0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Immunic this week, compared to 3 articles on an average week.Search Interest29 people have searched for IMUX on MarketBeat in the last 30 days. This is an increase of 61% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Immunic to their MarketBeat watchlist in the last 30 days. This is a decrease of -45% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immunic insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Immunic is held by insiders.Percentage Held by Institutions51.82% of the stock of Immunic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunic's insider trading history. Receive IMUX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunic and its competitors with MarketBeat's FREE daily newsletter. Email Address IMUX Stock News HeadlinesIMUX stock touches 52-week low at $0.92 amid market challengesFebruary 12 at 11:24 PM | msn.comAnalysts Set Immunic, Inc. (NASDAQ:IMUX) Price Target at $12.67February 11, 2025 | americanbankingnews.comElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors have all turned to my business partner and I for our thoughts on the market. And with every investor in America wondering what Elon is going to do now that he's in Washington, this is what we tell themFebruary 15, 2025 | Altimetry (Ad)EQS-News: Immunic to Participate in Investor and Scientific Conferences in FebruaryFebruary 4, 2025 | markets.businessinsider.comImmunic to Participate in Investor and Scientific Conferences in FebruaryFebruary 4, 2025 | prnewswire.comPromising Outlook for Immunic’s VidoCa in PMS: Favorable Risk/Reward and Key Metrics Drive Buy RatingJanuary 29, 2025 | markets.businessinsider.comImmunic Inc.January 22, 2025 | thestreet.comImmunic eyes transformative year ahead for MS therapy vidofludimus calcium - ICYMIJanuary 11, 2025 | proactiveinvestors.comSee More Headlines IMUX Stock Analysis - Frequently Asked Questions How have IMUX shares performed this year? Immunic's stock was trading at $1.00 on January 1st, 2025. Since then, IMUX shares have increased by 0.0% and is now trading at $1.00. View the best growth stocks for 2025 here. How were Immunic's earnings last quarter? Immunic, Inc. (NASDAQ:IMUX) released its earnings results on Thursday, November, 7th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.02. Who are Immunic's major shareholders? Top institutional shareholders of Immunic include Adage Capital Partners GP L.L.C. (1.55%), Renaissance Technologies LLC (0.63%), Marshall Wace LLP (0.46%) and Barclays PLC (0.09%). Insiders that own company stock include Daniel Vitt, Andreas Muehler, Richard Alan Rudick, Glenn Whaley, Duane Nash and Joerg Neermann. View institutional ownership trends. How do I buy shares of Immunic? Shares of IMUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immunic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunic investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Alibaba Group (BABA), CrowdStrike (CRWD), Viking Therapeutics (VKTX), BioXcel Therapeutics (BTAI) and Aldeyra Therapeutics (ALDX). Company Calendar Last Earnings11/07/2024Today2/15/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMUX CUSIPN/A CIK1280776 Webwww.immunic-therapeutics.com Phone(332) 255-9818Fax858-673-6843Employees70Year FoundedN/APrice Target and Rating Average Stock Price Target$12.67 High Stock Price Target$28.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,166.7%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,610,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-169.55% Return on Assets-118.96% Debt Debt-to-Equity RatioN/A Current Ratio2.71 Quick Ratio2.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.64 per share Price / Book1.56Miscellaneous Outstanding Shares90,080,000Free Float87,377,000Market Cap$90.08 million OptionableOptionable Beta1.87 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:IMUX) was last updated on 2/15/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredTop Picks for Trump’s Pro-Crypto America10,000% Crypto Opportunities in 2025 27 of the brightest minds in crypto share exclusive intel… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.